- |||||||||| Avastin (bevacizumab) / Roche, NOV-002 / Cellectar
Retrospective data, Journal: Mortality of early treatment for radiation-induced brain necrosis in head and neck cancer survivors: A multicentre, retrospective, registry-based cohort study. (Pubmed Central) - Aug 30, 2022
P=N/A
In the absence of data from randomised trials, our study will have an important implication for clinicians regarding the optimal timing of treatment for RN, and provides the foundation and supporting data for future trials on this topic. National Natural Science Foundation of China (81925031, 81820108026, 81872549, 81801229, 82003389), the Science and Technology Program of Guangzhou (202007030001), Young Teacher Training Program of Sun Yat-sen University (20ykpy106), Key-Area Research and Development Program of Guangdong Province (2018B030340001), the National Medical Research Council Singapore Clinician Scientist Award (NMRC/CSA-INV/0027/2018, CSAINV20nov-0021), the Duke-NUS Oncology Academic Program Goh Foundation Proton Research Programme, NCCS Cancer Fund, the Kua Hong Pak Head and Neck Cancer Research Programme, and the National Research Foundation Clinical Research Programme Grant (NRF-CRP17-2017-05).
- |||||||||| NOV-002 / Cellectar
Comparative transcriptomic analyses of 100,691 primary tumors from East Asian (EA) and North American (NA) men with prostate cancer (PCa) (Poster Area, Hall 4) - Jul 28, 2022 - Abstract #ESMO2022ESMO_3049;
Funding National Medical Research Council Singapore Clinician Scientist Award (NMRC/CSA-INV/0027/2018, CSAINV20nov-0021), National Research Foundation Proton Competitive Research Program (NRF-CRP17-2017-05), Ministry of Education Tier 3 Academic Research Fund (MOE2016-T3-1-004), the Duke-NUS Oncology Academic Program Goh Foundation Proton Research Programme, NCCS Cancer Fund, and the Kua Hong Pak Head and Neck Cancer Research Programme...Luminal B and PCa with high angiogenesis scores had worse DMFS (HR 2.98 [0.9-10.2]; HR 6.06 [1.3-28.2], respectively) in the EA cohort. Conclusions Herein, we validated the Decipher GC for prognostication, and using a large reference population of NA PCa tumors, identified several demographic-specific transcriptomic features, which may have implications on the efficacy of new therapeutic agents in EA men with PCa.
- |||||||||| NOV-002 / Cellectar
Enrollment change, Combination therapy: Efficacy of NOV-002 in Combination With Carboplatin in Chemotherapy-resistant Ovarian Cancer (clinicaltrials.gov) - Mar 10, 2015
P2, N=15, Completed,
Conclusions Herein, we validated the Decipher GC for prognostication, and using a large reference population of NA PCa tumors, identified several demographic-specific transcriptomic features, which may have implications on the efficacy of new therapeutic agents in EA men with PCa. N=25 --> 15
|
